By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199




GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

Company News
Medivir (MVRBF) Completes Transition Of Commercial Products To Fully Focus On Research And Development 3/16/2017 11:24:43 AM
Medivir (MVRBF)'s Nomination Committee Proposes New Board Of Directors Ahead Of 2017 AGM 2/24/2017 7:36:46 AM
Executive Management Team Members Increase Their Holdings In Medivir (MVRBF) 2/17/2017 10:46:00 AM
Christine Lind New CEO Of Medivir (MVRBF) Effective 1 April 2017 2/9/2017 7:00:08 AM
Medivir (MVRBF) Release: MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review Of Safety Data Enables Trial Continuation Without Any Modifications 2/1/2017 8:58:50 AM
Medivir (MVRBF) Release: Notice Of Extraordinary General Meeting Of Company 1/10/2017 11:50:26 AM
TetraLogic (TLOG) Announces Completion Of Sale Of SMAC Mimetic And HDAC Inhibitor Assets To Medivir (MVRBF) 12/29/2016 10:42:24 AM
Medivir (MVRBF) Completes The Divestment Of BioPhausia AB - A Transfer Of Approx. SEK 870m To The Shareholders Through A Share Redemption Offer Will Be Proposed 12/15/2016 8:17:39 AM
Medivir (MVRBF)'s Fusion Inhibitor For The Treatment Of Respiratory Syncytial Virus Infection, MIV-323, Enters Non-Clinical Development 12/14/2016 6:57:45 AM
Medivir (MVRBF): MIV-711 Osteoarthritis Trial: Successful Third Independent Review Of Safety Data And Trial Continues Without Any Modifications 12/8/2016 1:09:09 PM